Get the Stockscreener App
1.355
6.55%
-0.095
After Hours:
1.36
0.005
+0.37%
Biorestorative Therapies Inc stock is traded at $1.355, with a volume of 27,653.
It is down -6.55% in the last 24 hours and down -18.62% over the past month.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
See More
Previous Close:
$1.45
Open:
$1.48
24h Volume:
27,653
Relative Volume:
1.10
Market Cap:
$9.41M
Revenue:
$149.50K
Net Income/Loss:
$-6.96M
P/E Ratio:
-0.2847
EPS:
-4.76
Net Cash Flow:
$-6.37M
1W Performance:
-17.70%
1M Performance:
-18.62%
6M Performance:
+4.23%
1Y Performance:
-27.15%
1-Day Range:
$1.21
$1.48
1-Week Range:
$1.21
$1.78
52-Week Range:
$1.03
$3.6699
Biorestorative Therapies Inc Stock (BRTX) Company Profile
Name
Biorestorative Therapies Inc
Sector
Industry
Phone
(631) 760-8100
Address
40 MARCUS DRIVE, MELVILLE
Compare BRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| BRTX | 1.355 | 9.41M | 149.50K | -6.96M | -6.37M | -4.76 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Biorestorative Therapies Inc Stock (BRTX) Latest News
BioRestorative Therapies Provides Business Update and Financial Results for Q3 2024 - Defense World
Analyzing American Caresource (OTCMKTS:GNOW) & BioRestorative Therapies (NASDAQ:BRTX) - Defense World
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q3 2024 Earnings Call Transcript - Insider Monkey
BioRestorative Therapies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
BioRestorative Therapies earnings beat by $0.31, revenue fell short of estimates - Investing.com Canada
BioRestorative Therapies Q3 2024 Financial Update - TipRanks
BioRestorative Therapies Lower Back Candidate Shows Decrease In Pain, Increased Function - Benzinga
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data - OrthoSpineNews
BioRestorative's BRTX-100 Shows 100% Success Rate in Early Back Pain Trial Data | BRTX Stock News - StockTitan
BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
BioRestorative Therapies Enters at-the-Market Offering Agreement with Rodman & Renshaw LLC - Defense World
Roth Capital Issues Optimistic Outlook for BRTX Earnings - Defense World
BioRestorative Therapies to Announce Phase 2 Trial Data - TipRanks
Research Analysts Offer Predictions for BRTX Q1 Earnings - Defense World
BioRestorative Therapies inks new equity deal - Investing.com
BioRestorative Therapies inks new equity deal By Investing.com - Investing.com UK
BRTXBioRestorative Therapies, Inc. Latest Stock News & Market Updates - StockTitan
BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium - The Manila Times
BioRestorative to Present Expanded BRTX-100 Phase 2 Trial Data for Chronic Back Pain Treatment | BRTX Stock News - StockTitan
Broadrick Dale reduces stake in BioRestorative Therapies, Inc. with $1,756 sale - Investing.com
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health - GlobeNewswire
BioRestorative Therapies (OTCMKTS:BRTXQ) Reaches New 12-Month HighShould You Buy? - MarketBeat
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program - GlobeNewswire
BioRestorative Therapies (OTCMKTS:BRTXQ) Sets New 1-Year HighHere's Why - MarketBeat
BioRestorative Therapies (OTCMKTS:BRTXQ) Hits New 12-Month HighStill a Buy? - MarketBeat
BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events - GlobeNewswire
BioRestorative Therapies (OTCMKTS:BRTXQ) Sets New 52-Week HighWhat's Next? - MarketBeat
BioRestorative Therapies (OTCMKTS:BRTX) Stock Price Passes Below 50-Day Moving Average – Here’s Why - Defense World
BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire
BioRestorative Therapies (OTCMKTS:BRTXQ) Sets New 1-Year High at $1.79 - Defense World
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update - Defense World
BioRestorative Therapies (OTCMKTS:BRTXQ) Reaches New 12-Month High at $1.91 - Defense World
BioRestorative Therapies expands stock incentive plan - Investing.com
Acadian Asset Management LLC Sells 107,112 Shares of BioNTech SE (NASDAQ:BNTX) - MarketBeat
Biodexa Pharmaceuticals Announces ADR Ratio Change - TipRanks
Beasley Broadcast Group Approves Reverse Stock Split - RADIO ONLINE
BioLife Solutions (NASDAQ:BLFS) Stock Price Up 5.8% - MarketBeat
BioNTech Is More Than a Covid-19 Stock. It’s Having a Great September. - Barron's
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Meiji Yasuda Life Insurance Co - Defense World
Mutual of America Capital Management LLC Purchases Shares of 108,713 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
Beasley Does a Reverse Stock Split - Radio World
Biomarin Pharmaceutical Inc. [BMRN] Shares Fall Approximately -19.71% Over the Year - Knox Daily
Daily Market Movement: BioNTech SE ADR (BNTX) Sees a -7.29 Decrease, Closing at 115.62 - The Dwinnex
Royal Bank of Canada Reiterates Outperform Rating for Biogen (NASDAQ:BIIB) - MarketBeat
BioLife Solutions (NASDAQ:BLFS) Shares Down 2% - Defense World
Beasley Broadcast Group’s Reverse Stock Split: What Shareholders Need to Know - TALKERS magazine
Massachusetts Financial Services Co. MA Boosts Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) - Defense World
Banzai announces 1-for-50 reverse stock split - TipRanks
Beasley Media Group Implementing Reverse Stock Split. - Insideradio.com
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up to $26.19 - Defense World
Bio-Rad Laboratories, Inc. (NYSE:BIO) Expected to Post Q3 2024 Earnings of $2.13 Per Share - MarketBeat
Biorestorative Therapies Inc Stock (BRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):